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Abstract
Background: The PGC-1 related coactivator (PRC), which shares structural and functional features with PGC-1a, is believed
to regulate several metabolic pathways as well as mitochondrial biogenesis. Its involvement in the early programming of
cell proliferation suggests the existence of finely regulated crosstalk between mitochondrial functions and the cell cycle
status.
Methodology/Principal Findings: PRC-regulated pathways were explored in a cell-line model derived from mitochondrial-
rich tumours with an essentially oxidative metabolism and specifically high PRC expression. The functional status of
mitochondria was compared to the results of microarray analysis under conditions of temporal PRC inhibition. To specify the
fine PRC regulation, the expression levels of the genes and proteins involved in the oxidative phosphorylation process were
studied by real time quantitative PCR and western blotting. As in earlier studies on PGC-1a, we investigated the role of nitric
oxide in PRC-regulated mitochondrial biogenesis and determined its action in the control of the phosphorylation status of
the mitogen-activated protein kinase pathway.
Conclusion/Significance: We found that nitric oxide rapidly influences PRC expression at the transcriptional level. Focusing
on mitochondrial energetic metabolism, we observed that PRC differentially controls respiratory chain complexes and
coupling efficiency in a time-dependent manner to maintain mitochondrial homeostasis. Our results highlight the key role
of PRC in the rapid modulation of metabolic functions in response to the status of the cell cycle.
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Introduction
Several essential cellular functions of mitochondria depend on a
high degree of functional interaction between the nuclear and
mitochondrial genomes. Of the hundred structural subunits that
make up the oxidative phosphorylation (OXPHOS) complexes, 13
are encoded by the mitochondrial genome. The mechanisms
governing the coordination of the multiple transcription factors
involved in mitochondrial biogenesis have been partly explained
by the discovery of the PGC-1 coactivator family [1]. Three
members of this family – PGC1a, PGC1b and PRC – regulate
several functions, including adaptative thermogenesis, glucidic
metabolism, fatty acid oxidation and mitochondrial metabolism,
via functional interactions with various transcriptional factors.
Mitochondrial biogenesis is controlled by PGC mainly through
interactions with nuclear respiratory factors, NRF-1 and NRF-2,
and may be induced via p38 mitogen-activated protein kinase. In a
cell-selective manner, the efficiency of the oxidative phosphoryla-
tion process may also be regulated by PGC through the
transcriptional control of uncoupling proteins (UCPs) [2].
PGC-1a is expressed in organs and tissues with high energetic
needs, such as heart, liver, skeletal muscle, brown adipose tissue,
brain and kidney. In contrast, the expression of the PGC-1 related
coactivator (PRC) depends on the cell cycle, and plays a role in the
integration of pathways directing the mitochondrial respiratory
function and cell growth [3]. PRC shares key structural motifs with
PGC-1a, interacting with and transactivating the promoters of
NRF-1 target genes in a similar manner [4,5]. Other transcription
factors targeted by PGC-1a have been studied as potential targets
for PRC. Weak interactions between PRC, on one hand, and
PPARc,T R b and RAR, on the other, reflect the divergence
between PRC and PGC-1a; however, strong interactions between
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been identified [6,7]. The nuclear transcription factors involved in
mitochondrial biogenesis are not exclusive to this process but
contribute to integrating the expression of mitochondrial proteins
with other cellular functions. Thus, PRC has been shown to
control cell growth through mechanisms that seem to be
independent of its effects on mitochondrial function [3]. PRC
has also been described as a positive regulator of respiratory chain
expression; however, the precise role played by PRC in the
complex functions involved in mitochondrial biogenesis and cell
growth remains to be elucidated.
Deregulation in the functional status of mitochondria can have
a feedback effect on nuclear transcriptional machinery [8,9]. It has
been suggested that this retrograde signalling influences the
bidirectional communication between the nucleus and mitochon-
dria through a PGC-1 dependent pathway [10]. Mitochondrial
functions are regulated by complex mechanisms in which nitric
oxide (NO) is a key factor. The mitochondrial effect of NO is bi-
phasic depending on its production level. Thus, NO is known to
induce the production of reactive oxygen species (ROS) and
trigger redox signalling [11]. It directly binds the haem-copper
oxidases of complex IV and leads to reversible inhibition of the
respiratory chain in an acute response. In a long term effect, a
nitric oxide-cGMP-dependent pathway has been shown to control
mitochondrial biogenesis through the PGC-1a pathway [12]. The
overexpression of NO, cGMP, or eNOS (endothelial nitric oxide
synthase) was found to dramatically increase the number of
mitochondria in a range of cell lines. This overexpression, related
to a high production of PGC-1a, leads to the formation of
functionally efficient mitochondria in terms of oxidative phos-
phorylation. Interestingly, constitutive NO synthase – like eNOS –
generates a low concentration of NO, which acts mainly as a
second messenger to maintain cell homeostasis [13]. Moreover,
eNOS was suspected of being one of the target genes of the
retrograde signalling [14]. Since PRC presents the characteristics
of an early gene product, it is likely to be involved in the rapid
response to retrograde signals [7].
We have demonstrated in thyroid oncocytoma, which constitute a
model of mitochondrial-rich tumours, a high rate of PRC induction,
with no disruption of mitochondrial functions [15]. The PRC-
induced effects were confirmed in the XTC.UC1 thyroid cell line,
which thus offered a useful model for investigating the coordination
of the nuclear and mitochondrial genomes [16,17]. In these
mitochondrial-rich cells, we found an increased expression of eNOS,
clearly produced by follicular thyroid cells [18,19]. To further
appreciate the importance of the nuclear-mitochondrial crosstalk
mediated by PRC, we searched for the cellular programs regulated
by PRC in the oxidative XTC.UC1 human oncocytic thyroid cell
line, using genome-wide expression profiles of PRC SiRNA versus
those of negative control cells. We compared the pattern of PRC
inhibition with the activation of mitogen-activated protein kinase
(MAPK). We investigated the effect of NO on the induction of PRC
in the oncocytic cells compared to a non-oxidative BCPAP cell line
derived from a papillary thyroid carcinoma. We focussed on the
various functional features of PRC compared to those of PGC-1a,
especially with respect to the rapid response required to maintain
mitochondrial and cell homeostasis.
Results
PRC-Mediated Mitochondrial Biogenesis Depends on the
Level of Nitric Oxide Production
At T0, the endogenous NO was significantly higher (4.2 fold on
average) in XTC.UC1 cells than in BCPAP cells (Figure 1A). Since
identical results were obtained with the nitric oxide donor SNAP
at concentrations of 50 mM and 100 mM, we considered only those
of SNAP at 100 mM, this concentration being likely to produce
100 nM equivalent NO during several hours [20]. From T0 to
T72, daily SNAP treatment induced comparable NO concentra-
tions in the two cell lines, with a 1.6 fold increase in XTC.UC1
cells and a 1.7 fold increase in BCPAP cells. At T96, the use of the
DAF-2/DA dye as an NO probe showed that the NO level
decreased sharply for XTC.UC1 cells. This was associated with a
12-fold increase of ROS production, detected with a dihydroethi-
dium probe, for XTC.UC1 cells at T96, whereas ROS production
was stable at T48 and T72 (data not shown). The drastic decrease
in the NO level measured by the DAF2 dye at T96 could be
associated with the complete inhibition of complex IV activity and
Figure 1. Effect of 100 mM SNAP treatment during 96 h on
XTC.UC1 and BCPAP cell lines (N=5 per cell line). 1A: Nitric oxide
measurement with the FACScan cytometer (10 mM final DAF2/DA dye).
Results are expressed in arbitrary fluorescent units as mean values6SEM.
*P#0.05 versus T0. **P#0.05 versus T0 and T72. 1B: Evaluation of protein
nitration by Western blotting using antibody raised against nitrotyrosine-
modified proteins. Immunoblots are quantified by densitometric analysis
and expressed in arbitrary units (relative to a-tubulin) as mean
values6SEM. *P#0.05 versus T0.
doi:10.1371/journal.pone.0007964.g001
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chain could have induced an oxidative stress that, combined with
the high NO level, may have produced peroxynitrite. However,
contrary to probes measuring oxidative stress, the DAF2 probe
was unable to detect peroxynitrite formation [21]. For BCPAP
cells, NO production continuously increased at T96 up to 2.2 fold
from T0. The profile of nitrotyrosine-modified proteins showed
that the 100 mM SNAP treatment induced a significant increase in
protein nitration in XTC.UC1 cells from T48 whereas protein
nitration had not increased significantly in BCPAP cells at T96
(Figure 1B).
Regarding the mRNA expression of genes involved in
mitochondrial biogenesis (NRF-1, ND5 and PRC) and mitochon-
drial ROS detoxification (SOD2), we showed that the 100 mM
SNAP treatment induced nuclear gene expression from T48,
whereas mitochondrial gene ND5 expression was significantly
induced from T96 in XTC.UC1 cells (Figure 2). No significant
induction of genes involved in mitochondrial biogenesis was
observed in BCPAP cells up to T96 of SNAP treatment. However,
the SOD2 expression level had increased significantly at T96
compared to the T0 level.
PRC Expression Is Regulated at the Transcriptional Level
In XTC.UC1 cells synchronized by serum starvation for two
days, we compared the PRC mRNA expression level during 48 h
of 20% serum and PRC SiRNA and/or SNAP treatment
(Figure 3A). The expression profile during 20% serum treatment
was considered as a control. After 48 h of continuous SNAP
treatment, there was a 2.2-fold increase of PRC induction
compared to the 48 h control. SiRNA treatment reduced PRC
expression by 70% at 48 h while SiRNA and SNAP used in
combination led to PRC re-expression up to 1.4 times the 48 h
control value. Moreover, PRC mRNA expression was rapidly re-
induced to a significant level after 6 h of treatment with
SNAP+SiRNA (5.660.6 relative PRC mRNA) compared to the
level after 6 h of treatment with SiRNA alone (3.560.4 relative
PRC mRNA, P#0.05).
The expression of PRC and that of three genes involved in
mitochondrial biogenesis (NRF-1, TFAM and COX5B) was
significantly down-regulated when the NO/cGMP pathway was
inhibited by the protein kinase G (PKG) inhibitor KT5823 at
1 mM (Figure 3B). This showed the involvement of the NO/cGMP
pathway in the regulation of PRC expression, which decreased
from 2.260.1 to 0.860.1 relative PRC mRNA with KT5823
treatment (P#0.05).
Figure 2. The expression of nuclear genes (PRC, NRF-1 and
SOD2) and the mitochondrial gene (ND5) after 100 mMS N A P
treatment of XTC.UC1 and BCPAP cells during 96 h. Data are
expressed in relative units (mRNA copies number of a specific gene/copy
numberofb-globinmRNA)andexpressedintermsoftheT0ratioasmean
values6SEM. *P#0.05 versus T0. N=5 per cell line and time of treatment.
doi:10.1371/journal.pone.0007964.g002
Figure 3. Effects of mRNA expression in XTC.UC1 cells during
20% serum induction and 100 mM SNAP and/or 30 nM PRC
SiRNA treatment. Relative units (PRC mRNA copy number/b-globin
copy number) expressed in terms of the T0 ratio as mean values6SEM.
N=5 per time of treatment. 3A: The variation of PRC mRNA during 48 h
of the different treatments. Except for T48 SiRNA, all samples differed
significantly from T0 (P#0.05). *P#0.05 versus T6. 3B: The variation of
NRF-1, TFAM and COX5B mRNA at T24 of SNAP 100 mM and/or KT5823
1 mM (protein kinase G inhibitor) treatments compared to control T0. All
samples differed significantly from T0 (*, P#0.05) or from those with
100 mM SNAP treatment ({, P#0.05).
doi:10.1371/journal.pone.0007964.g003
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Nuclear-Mitochondrial Crosstalk
We examined the gene expression pattern of PRC SiRNA and
control cells during the 48 h SiRNA treatment (Figure 4A). We had
previously verified the level of PRC expression during the kinetics of
inhibition by comparing PRC expression in SiRNA to a negative
control by quantitative RT-PCR. PRC expression was inhibited from
42% (0 h and 12 h) to 70% at 24 h and 74% at 48 h. The absence of
difference in the level of PRC inhibition between 0 h and 12 h may be
explained by the dependence of PRC expression on cell cycle
induction at 12 h even though PRC SiRNA had begun to act. Protein
level measurements showed that SiRNA treatment was also able to
inhibit PRC to more than 80% of the control after 24 h (Figure S1A).
Eight clusters of genes were differentially expressed between
PRC SiRNA and the control during 48 h of 20% serum induction
(Figure 4A). Gene ontology identified two clusters, 2 and 8, in
which mitochondrial functions were enriched, and two clusters, 5
and 6, in which the cell cycle functions were enriched (Table 1).
The comparison of the significant differential gene expression
between PRC SiRNA and the negative control, in each cluster and
at each time of treatment (Figure 4B), showed that some genes
were negatively regulated by PRC at a given time and positively at
another. This suggests that PRC regulates gene transcription
through interactions with transcriptional factors in either a positive
or a negative manner. We confirmed the differential expression of
nine genes selected from clusters 2, 5 and 6 by quantitative RT-
PCR analysis on 5 independent SiRNA experiments (Figure S1C).
A Pearson correlation of 90% was found between results of
microarray analysis and real-time RT–PCR.
We searched for transcriptional factors involved in the PRC-
regulating pathway in clusters 2 and 6 where ontological terms
were enriched in mitochondrial metabolism and the cell mitotic
Figure 4. Microarray analysis of the XTC.UC1 cell line after transfection with either PRC SiRNA (PRC) or scramble as a negative
control (Sc). The expression profiles were obtained at T12, T24 and T48 after SiRNA transfection and normalized to serum or scramble values (N=4
per time). The XTC sample represents the gene expression profile of the cell line before transfection. 4A: Global clustering of PRC SiRNA and negative
control (scramble) samples normalized by serum induction. Eight clusters were selected on significant differential genes for all time of SiRNA
treatment (P#0.03). 4B: Significant over- and under-expressed genes in SiRNA samples compared to negative control (scramble) samples for each of
the 8 clusters previously identified by serum centring. At the right side of each cluster (***) are represented the genes differentially expressed (over-
expressed in red, and under-expressed in green) at T12, T24 and T48 (P#0.03) in PRC SiRNA compared to matched negative controls for time. Grey
bars separate times of treatment as T0, T12, T24, and T48.
doi:10.1371/journal.pone.0007964.g004
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operated through NRF-1, NRF-2 and ERR1 interactions, whereas
PRC-negative regulation acted mainly through SREBP1, CREB1
and MAZ interactions (Figure 5A). Cluster 6 showed that PRC-
positive regulation depended on SP1, CREB1 and YY1 interac-
tions whereas PRC-negative regulation depended on NRF-2 and
Table 1. Description and gene ontology of the genes from the 8 clusters identified and normalized on serum induction,





Differential gene expression PRC
vs Negative control (p#0.05)
Principal Functional annotations compared to
5225 filtered cDNA probes P –value
Over Under
1 786 209 127 G-protein activating pathway 0.0013
Protein kinase and phosphatase activity 0.0017
Regulation of signal transduction 0.0055
Regulation of MAPK activity 0.0068
Regulation of angiogenesis 0.0116
2 538 260 65 Oxidative phosphorylation 0.0001
Response to stress 0.0001
Carboxylic acid metabolism 0.0001
Mitochondrial respiratory chain complex assembly 0.0011
Fatty acid metabolic process 0.0039
Nitrogen compound metabolic process 0.0049
Mitochondrion organization and biogenesis 0.0245
3 131 38 23 Chromatin remodelling 0.0026
Regulation of cytoskeleton organization 0.0026
Cell to cell signalling 0.0121
Cell junction assembly 0.0218
Transcription coactivator activity 0.0193
4 243 21 114 Ribosome biogenesis and assembly 0.0001
Vesicle organization and biogenesis 0.0001
Protein-RNA complex assembly 0.0002
Nucleic acid metabolic process 0.0006
mRNA processing 0.0022
5 57 48 3 Protein targeting to membrane 0.0030
DNA methyl transferase activity 0.0074
Spindle elongation process 0.0107
Cell cycle process 0.0302
Regulation of S phase of mitotic cycle 0.0318
6 198 91 48 Regulation of M phase of cell mitotic cycle 0.0001
Microtubule cytoskeleton organization 0.0001
Chromosome segregation 0.0002
Regulation of cyclin-dependent protein-kinase activity 0.0016
Regulation of transcription factor activity 0.0041
7 386 61 123 Response to DNA damage 0.0001
Response to endogenous stimulus 0.0001
Base excision repair process 0.0006
Mismatch repair process 0.0006
Primary metabolism process 0.0013
8 267 35 69 Mitochondrial ribosome assembly 0.0001
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ranging from 22–49% in the two gene clusters, was relevant of
their involvement in the regulation of these genes compared to the
relatively low frequency (2–15%) for the other genes of the
microarray.
Oxidative Phosphorylation Is Finely Regulated by PRC
Functional analysis of the respiratory chain complexes showed
that complexes I and III activities were rapidly down-regulated
when PRC inhibition was effective (T24 of SiRNA treatment
referred to T12). This was associated with increased complex IV
activity and better coupling between respiration and ATP
synthesis (Figure 6A). At T48, the activity of each of the four
complexes decreased; although the coupling was more efficient
compared to that at T24 (JC-1 results), the ATP level was
significantly lower at T48 than at T12. This may be related to a
PRC-regulation of UCPs, as described for PGC-1a [2].
Regarding the expression of selected genes coding for complex
IV subunits, the mitochondrial-encoded gene COII was down-
regulated at T24, together with a decrease in mtDNA copy
number (Figure 6B). The expression of nuclear-encoded complex
IV subunit genes was more variable. There was a large variation in
the expression of COX15 during PRC inhibition whereas the
expression of COX5B decreased proportionally to that of COII.
The expression of COX15 at T24 increased by 1.8 fold compared
to that at T12, followed by a sharp decrease to 8% of the control
value at T48. This may be related to the great difference in
complex IV activity observed between T24 and T48. Taken
together, these results showed that complexes I, III and IV were
primarily regulated by PRC, in particular with regard to the
Figure 5. Focus on clusters 2 and 6 for PRC-regulated genes. 5A: PRC-sensitive under- and over-expressed genes in cluster 2. 5B: PRC-sensitive
under- and over-expressed genes in cluster 6. The arrow represents the differential genes in SiRNA PRC compared to negative controls at times T12,
T24 and T48. Using MSignDB software (GSEA, MIT, MI, USA), the promoters of selected genes, positively or negatively regulated by PRC, were
explored for transcription factor motifs. The percentage of genes in which the motif for a selected transcription factor was found is indicated in
brackets. Highly significant ontologies are shown (P#0.01, GOMiner software [50]).
doi:10.1371/journal.pone.0007964.g005
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activity of the complex IV in the first 12 h of PRC invalidation.
Although these changes may have caused a functional default in
the respiratory chain inducing oxidative stress, the expression of
SOD2, a gene coding for a protein involved in superoxide
detoxification, had not significantly decreased even at T48.
However, the extension of the SiRNA treatment beyond T48
led to significantly down-regulated results (data not shown). The
protein expression of several subunits from each OXPHOS
complex decreased significantly at T48 for the three complexes I,
II and IV, but the decrease was not significant for complexes III
and V (Figure 6C). However, the gene and protein expressions of
the different OXPHOS complexes were correlated so that global
down-regulation was observed with PRC inhibition at T48
compared to T12.
PRC Regulates Phosphatase/Kinase Activity
A phosphospecific antibody microarray for the MAPK signall-
ing pathway was set up to compare the phosphorylation status of
direct as well as indirect MAPK targets so as to determine whether
PRC was required for the phosphorylation of MAPK targets. This
antibody array included 93 highly specific and well-characterized
phosphospecific antibodies for proteins in the MAPK pathway,
each with six replicates (the raw data are shown in Table S1). The
paired antibodies for the same, but unphosphorylated, target sites
were also included in the array to allow determination of the
relative level of phosphorylation. Using a cutoff ratio of 0.8, we
identified 11 sites that were hypophosphorylated in PRC SiRNA
cells at T48 compared with control cells. These sites were involved
in the regulation of the activity of seven proteins: ASK1 (P83 and
P966), TP53 (P18 and P46), ATF-2 (P69-51), c-JUN (P63) SAP/
JNK (P183), ELK1 (P383 and P389), ESR1 (P167) and Stahmin-1
(P15). Except for Stahmin-1, all these proteins are involved in
the redox-sensitive pathway controlled by the activation of Ask1
protein by phosphorylation. A significant decrease in the phos-
phorylation status of Ask1(Ser83) and Elk1(Ser383) was confirmed
by western blot analysis on five independent PRC SiRNA treated
cells compared to controls; the decrease was 32% for Ask1 and
58% for Elk1 (p,0.05) (Figure S1B).
Discussion
PRC, a member of the family of PGC1 transcriptional
coactivators, is expressed more abundantly in proliferative cells
than in growth-arrested cells. Several studies have demonstrated
the important role played by these coactivators in modulating
tissue energetic resources [22]. In the mitochondrial-rich tumour
model we investigated, PGC-1a expression remained very low,
being induced neither by serum nor in compensation to PRC
repression.
As reported by other authors [3,6], we showed that the nuclear
and mitochondrial genes of the respiratory chain were up-
regulated in accordance with PRC induction in a time-dependent
manner. We also observed an induction of SOD2 expression that
had been previously shown to be regulated by PGC-1a [23].
However, the rapid action of the PKG inhibitor on both PRC
expression and the nuclear genes controlling respiratory chain
biosynthesis indicated that, in the XTC.UC1 cell model,
mitochondrial biogenesis required the induction of the NO/
PRC pathway. The increase in PRC expression observed with
combined PRC invalidation and SNAP treatment may be
explained by the role of PRC in the rapid response to change in
the status of the cell cycle [7]. An activating process by
phosphorylation, as described for PGC-1a, has not so far been
reported for PRC. We observed that an activating process by
nitration could rapidly modulate PRC expression. This mecha-
nism has also been implicated in the regulation of several
transcription factors, such as CREB, c-Myc, Jun or Fos [24,25].
Figure 6. Functional and expression status of oxidative
phosphorylation during PRC SiRNA treatment. T12 of serum
induction during PRC SiRNA treatment was used as a reference to
explore the efficient PRC inhibition at T24 and T48. (N=5;*P#0.05). 6A:
Enzymatic activities of four complexes of the respiratory chain (I, II, III
and IV), total cell ATP and JC-1 ratios were measured on PRC SiRNA
treated cells and related to control scramble cells. The JC-1 ratio
represents the coupling efficiency between the respiratory chain and
ATP synthesis. 6B: cDNA and mtDNA copy numbers of selected genes
during PRC inhibition. The mitochondrial gene (COII) and the nuclear
genes (COX5B, COX15) correspond to subunits of complex IV of the
respiratory chain. Their expression, associated to mitochondrial SOD2
gene expression and mtDNA copy number were measured at T12, T24
and T48 of PRC SiRNA treatment and referred to the control scramble.
6C: Western blot analysis of subunits from each of the five complexes of
OXPHOS using the MS601 antibody cocktail (Mitosciences, Eugene, OR,
USA) during SiRNA treatment against PRC. Complex I (NDUFB8, 20 KDa),
complex II (Ip subunit, 30 KDa); complex III (Core 2:40 KDa); complex IV
(COX2, 24 KDa); complex V (ATPsynthase F1a, 58 KDa), relative to a-
tubulin (65 KDa). Measurements of SiRNA treatment at T12 and T48 are
referred to the negative control.
doi:10.1371/journal.pone.0007964.g006
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previously reported that the high cellular level of NO was related
to the induction of eNOS synthesis in follicular thyroid cells [26].
The activation of eNOS by the PI3K-AKT pathway has been
recently implicated in tumour maintenance [27]. This finding
may be particularly relevant in the context of mitochondrial-rich
tumours characterized by the absence of mutationsusually described
in thyroid tumours of follicular origin [28]. In contrast, BCPAP cells
were unable to activate the PRC pathway, even when NO increased
through SNAP treatment. Independently of the mitochondrial
quantity and the specific growth media, there was a great difference
in the mitochondrial expression profile and functions: while
XTC.UC1 cells displayed an oxidative metabolism, BCPAP cells
were mainlyengaged ina glycolytic process [19].Thissuggested that
defects of the mitochondrial function in BCPAP cells may have
induced a retrograde pathway modifying the status of cell
phosphorylation [29]. Thus, the action of PRC in controlling the
redox status should be taken into account in relation to cell
transformation and cancer.
Our microarray data on PRC inhibition may be compared with
the results of a recent study using a PRC ShRNA approach [3].
The use of SiRNA and ShRNA allowed us to distinguish between
the different temporal roles played by PRC, with SiRNA revealing
the short term effects and ShRNA indicating the chronic action of
PRC inhibition. However in both studies, a 50% decrease of PRC
mRNA was sufficient to demonstrate the specific regulatory
functions of this coactivator with complete inhibition of its protein
expression. The effects on the OXPHOS process were severe
probably because of the lack of functional compensation by other
members of this family of coactivators, as suspected following
studies on PGC-1a and PGC-1b null mice [30,31]. Contrary to
reports on ShRNA PRC knockdown [3], we identified a decrease
in mtDNA content that may be primarily related to the decrease in
OXPHOS activity. We postulate that long term PRC inhibition
by ShRNA could induce compensatory mechanisms to maintain
mitochondrial functions used for other cellular metabolisms. Using
SiRNA, we have defined the positive as well as the negative
regulations mediated by PRC through specific transcription
factors. These may represent the direct and indirect transcriptional
effects of the PRC coactivator. Thus, the PRC factor should be
seen as a physiological integrator of energetic metabolism in other
biological processes.
Focusing on clusters ontology, we showed that negative PRC
regulation could be exerted on the biogenesis of the cytoskeleton and
organelles. This should be compared with the surprising regulation of
mitochondrial complex IV activity during SiRNA treatment. While
complex IV activity has been previously related to PRC expression
[3], the time-related regulation we report has never been described so
far. Indeed, the analysis of the expression of some mitochondrial
and nuclear-encoded genes of complex IV showed that COX15
expression varied in a manner opposite to that of other genes. This
differential expression identified on microarray data was confirmed
by real-time quantitative PRC analysis. The role of COX15 in the
assembly of human complex IV has recently been emphasized [32].
COX15 was also found to be an essential component of the catalytic
centre of the complex. This PRC regulation seems to be independent
of a direct NO effect on the haem-copper of complex IV as there is a
correlation between the activity of this complex and the expression of
COX15 mRNA. We postulate that PRC ensures a rapid adaptation
to the cellular environment through the regulation of a few target
genes such as COX15. It separately regulates the expression of
OXPHOS subunits, leading to a rapid modulation of mitochondrial
functionality by integrating the regulation of complex IV activity with
coupling efficiency and ROS detoxification processes.
We associated PRC functions with some PGC-1a regulated
functions, such as chromatin remodelling, RNA splicing, translation
and angiogenesis [33,34]. Regulation of the cell cycle by PRC could
be compared to the regulation of PGC-1a and PGC-1b by
nutritional and hormonal signals as well as by circadian pacemakers
[35]. It has recently been described that the ubiquitous PRC
member could support the basal energetic cellular needs when
cycling progression from the G1 phase [3,6,36]. The rapid
regulation of complexes I and III, as well as the specific modulation
of complex IV activity we observed, confirmed the key role of PRC
for the rapid adaptation of cellular energy demand. The effects of
PRC on the M-phase of the cell cycle have not been described so
far. We suggest that PRC coordinates cell-cycle phases with
mitochondrial metabolism through both positive and negative
interactions with CREB1 and NRF-2 transcription factors. Previous
studies have clearly associated CREB1 and NRF2 with the
regulation of genes involved in energetic metabolism as well as
thecellcycle[37,38].Eventhoughtheseresultsaresupportedbythe
frequency of representation for motifs associated with these
transcription factors in specific clusters, they need to be confirmed
by results obtained with the chromatine-immunoprecipitation
technique.
Some pathways, such as those of the phosphatase/kinase
activities and vesicle organization, also seem to be specifically
related to PRC [3]. Interestingly, the MAPK profile of PRC-
inhibited cells showed a significant decline in the phosphorylation
level of proteins involved in the ASK1 signalling pathway. ASK1,
a serine/threonine protein kinase, is activated by the exposure of
cells to various stimuli, including tumour necrosis factor-a, Fas
ligand and hydrogen peroxide [39]. It lies upstream of a major
redox-sensitive pathway leading not only to the induction of
apoptosis but also to cell proliferation and differentiation [40]. The
majority of proteins involved in the control of the cell cycle have
been shown to be redox-sensitive with functions in the G1 and
G2/M phases [41]. Since the G2/M phase is in a more reduced
state than the G1 phase, oxidant-sensitive proteins may be
temporally regulated by the oscillation of the intracellular redox
environment [42]. We postulate that PRC may represent the
redox sensor enabling the initiation of the retrograde signalling
pathway, especially in a cellular model presenting a balance
between the production of nitric oxide and superoxide. Interest-
ingly, eNOS activity has also been shown to be redox-sensitive
[43]. Further studies will be needed to clarify the temporal role of
PRC in the integrative regulation of cell metabolism.
In conclusion, we have identified several new pathways
regulated by the PRC coactivator. Focusing on OXPHOS, we
showed that the PRC-regulation of this process differed from that
of PGC-1a. The nuclear OXPHOS genes were tightly controlled
by PGC-1a but less so by PRC. Nevertheless, other genes such as
COX15 were found to be more specifically regulated by PRC than
by PGC-1a. This precision control of mitochondrial energy
metabolism should be placed in the context of the complex
regulation of the cell cycle. Our study showed that the eNOS/
PRC signalling pathway can modulate the cell cycle by regulating
the intracellular redox status. The action of PRC, complementary
to that of other PGC-1 factors, should therefore be further
explored, especially in the case of metabolic diseases.
Materials and Methods
Cell Lines and SNAP Treatment
Two human thyroid cell lines, XTC.UC1 and B-CPAP, were
used.TheXTC.UC1cellline wasestablishedfromanoncocyticcell
thyroid carcinoma. The growth medium consisted of Dulbecco’s
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calf serum (Seromed, Biochrom AG, Berlin, Germany), 100 U/mL
penicillin, 100 mg/mL streptomycin, 0.25 mg/mL fungizone, and
10 mU/mL thyrotropin (TSH) (Sigma-Aldrich, Saint Louis, MO,
USA). The B-CPAP cell line was established from a human
papillary thyroid carcinoma cultured in RPMI-1640 medium with
10% foetal calf serum, 100 U/mL penicillin, 100 mg/mL strepto-
mycin, 0.25 mg/mL fungizone. Except for the TSH and the foetal
calf serum, all the products were obtained from Gibco BRL (Life
Technologies, Paisley, United Kingdom).
The two cell lines were treated once a day for four days with the
nitric oxide donor SNAP (S-nitroso-N-acetyl-D,L-penicillamine,
EMD, San Diego, CA, USA) at a final concentration of either 50
or 100 mM in the selected medium. Except for the microarray
analysis, which was performed in quadruplicate (N=4), all the
assays were performed in quintuplicate (N=5). To control the
mediating effect of NO/cGMP on PRC expression, cells were pre-
treated with 1 mM of the protein kinase G inhibitor KT5823
(EMD, San Diego, CA, USA) 30 minutes before SNAP treatment
(100 mM) during 24 h.
Flow Cytometry Analysis
XTC.UC1 cells were exposed at 37uC for 20 minutes to 5 mg/
mL JC-1 (5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazol-
carbocyanine) or for 30 minutes at pH 7 to 10 mM DAF-2/DA
(4,5-diaminofluorescein diacetate) before trypsin treatment. The
two dyes were purchased from EMD, San Diego, CA, USA.
The cells were then harvested, washed twice with PBS, and
analyzed on a FACScan flow cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA). Cultured cells, untreated with dyes, were used as a
negative control to determine the FACS gating. JC-1 emits red
fluorescence (aggregates) when sequestered in the mitochondrial
membrane of healthy cells and emits green fluorescence (monomers)
when released into the cytoplasmic compartment of the cell. At the
depolarized membrane potential (2100 mV), the JC-1 green
monomer emission peaks at about 527 nm. At the hyperpolarized
membrane potential (2140 mV) the red emission of the JC-1
aggregates shifts towards 590 nm. The red/green ratio represents
the modification of mitochondrial functionality during treatment.
DAF-2/DA is a cell-permeable derivative of DAF-2 presenting an
emission peak at about 515 nm, and which reacts neither with stable
oxidized forms of NO, such as NO2
2 and NO3
2, nor with other
reactive oxygen species, such as O2
2,H 2O2,a n dO N O O
2 [44].
Quantitative PCR Analysis
MtDNA and cDNA quantifications were performed on a
Chromo4 apparatus (Bio-Rad, Hercules, CA, USA) using SYBR
Green I dye as a fluorescent signal (iQ sybrGreen supermix, Bio-
Rad), according to the manufacturer’s recommendations. For
mtDNA quantification, primers were located at the following
nucleotide positions: forward, 3254–3277 (in the ND1 gene), and
reverse, 3412–3391 (in the tRNA
Leu gene). The mtDNA copy
number was expressed in terms of the copy number of a 110-bp
fragment of the b-globin gene. For cDNA quantification, the
expression of 16 selected genes (14 nuclear genes: PRC, PGC-1a,
NRF-1, COX5B, COX15, TFAM, SOD2, ALDH6A1, OSGIN2,
PRKAA2, CDCA3, CDC14B, CDC25C and b-GLOBIN and
two mitochondrial genes, COII and ND5) was measured by real-
time quantitative RT-PCR using the protocol previously described
[45] and the primers listed in Table 2.
Respiratory Chain Complex Activities and Cellular ATP
Respiratory chain complex activities were measured in cell
lysates, thermostatically maintained at 37uC, using a Beckman
spectrophotometer (DU800, Beckman Coulter, Fullerton, CA,
USA). Cells were resuspended in a cell buffer containing 250 mM
saccharose, 20 mM Tris, 2 mM EDTA, 1 mg/ml BSA, pH 7.2
(50 ml/10
6 cells).
To measure the activity of respiratory complexes I and II, the
cells were first disrupted by freezing in liquid nitrogen, followed by
rapid thawing at 37uC. Complex I activity was immediately
assayed on cell lysate (0.5610
6 cells) in a KH2PO4 buffer
(100 mM, pH 7.4), containing 1 mM KCN, 2 mM NaN3, and
0.1 mM ubiquinone-1. After incubation for 5 min, the reaction
was started by adding 0.3 mM NADH and the rate of dis-
appearance of NADH was monitored at 340 nm. Rotenone
(5 mM) was then added to determine the background rate.
Complex II (succinate ubiquinone reductase) activity was mea-
sured as described elsewhere [46], except that the background rate
was measured by the addition of thenoyltrifluoroacetone
(200 mM). Complex III (after a freeze-thaw cycle), complex IV
and citrate synthase (CS) activities were assayed as described
previously [47].
Table 2. Primer sequences used for real-time quantitative RT-
PCR.
ALDH6A1 Forward 59- CCA-GTC-CCA-CCT-GGT-ATT-CA-39
Reverse 59- CCC-GAC-CAA-TGA-CCT-CAT-TG-39
CDCA3 Forward 59- GTG-GAG-AGC-TCT-CCA-CAG-CC-39
Reverse 59- CCC-TTG-AGG-GCT-TGT-CGG-AG-39
CDC14B Forward 59- CCG-CTG-AAC-TTG-GCA-ATG-GG-39
Reverse 59- GCT-GCA-ATT-TGC-TCT-TTT-TCC-G-39
CDC25C Forward 59- GTC-ACC-TGG-ATT-CTT-CAG-GA-39
Reverse 59- GCA-GAT-GAA-CTA-CAC-ATT-GC-39
COII Forward 59 - AAC-AAA-CGA-CCT-AAA-ACC-TG – 39
Reverse 59 - GTG-AAC-TAC-GAC-TGC-TAG-AA – 39
COX5B Forward 59 - CCA-AAG-GCA-GCT-TCA-GGC-AC – 39
Reverse 59 - CAA-GGA-AGA-CCC-TAA-TCT-AG – 39
COX15 Forward 59 - CCT-CTC-GAT-GGT-AGA-TTG-GC – 39
Reverse 59 - CGG-AGG-GAG-TGC-AGT-GAC-AG – 39
ND5 Forward 59 - GGG-GAT-TGT-GCG-GTG-TGT-G – 39
Reverse 59 - CTT-CTC-CTA-TTT-ATG-GGG-GT – 39
NRF-1 Forward 59 - GGA-GTG-ATG-TCC-GCA-CAG-AA – 39
Reverse 59 - CGC-TGT-TAA-GCG-CCA-TAG-TG -39
OSGIN2 Forward 59- GAA-ATG-GAC-CCT-CAG-GAA-TA-39
Reverse 59- GGA-CCT-TTA-CCA-AGA-ACT-AC-39
PGC-1 Forward 59 - ACT-CAA-GTG-GTG-CAG-TGA-CC – 39
Reverse 59 - CTG-GGT-ACT-GAG-ACC-ACT-GC – 39
PRC Forward 59- GAT-CAG-AGC-AGC-GCT-GGG - 39
Reverse 59- CAC-TAG-CAG-CTC-TCT-CCC-C – 39
PRKAA2 Forward 59- GGA-GAA-CAT-CAA-TTA-ACA-GG-39
Reverse 59- CTG-CTG-AAA-GAG-CCG-CCT-GG-39
SOD2 Forward 59 - GCT-GCA-CCA-CAG-CAA-GCA-CC – 39
Reverse 59 - CCA-GCA-ACT-CCC-CTT-TGG-GT – 39
TFAM Forward 59 –CCG-AGG-TGG-TTT-TCA-TCT-GT- 39
Reverse 59 –CAG-GAA-GTT-CCC-TCC-AAC-GC-39
b-GLOBIN Forward 59 - GGT-GAA-CGT-GGA-TGA-AGT-TG – 39
Reverse 59 - GAG-CCA-GGC-CAT-CAC-TAA-AG – 39
doi:10.1371/journal.pone.0007964.t002
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USA) were added to 3.10
5 cells, growing in 200 ml of culture
medium, to measure the cellular ATP level. An ATP curve was
prepared as recommended by the manufacturers. Plates were
agitated for 2 min and incubated for 10 min at room temperature
before measuring the luminescence (Lumat 9507, Berthold
Technologies, Bad Wildbad, Germany). The ATP level was
expressed as ng per mg of total cell protein measured by the BCA
method (Pierce, Rockford, IL, USA).
PRC SiRNA
To knock down PRC expression in the XTC.UC1 cells, three
predesigned PRC SiRNAs (from Applied Biosystems, Foster city,
CA, USA) were tested in comparison to a random negative control
SiRNA (scramble, #4635). The PRC SiRNA (#121729) was
chosen for at least 70% of PRC mRNA expression knockdown.
For the study, 30 nM of this PRC siRNA were transfected in the
XTC.UC1 cells using siPORT NeoFX (Applied Biosystems) as
recommended by the manufacturer. To synchronize the cell cycle
for SNAP and/or PRC SiRNA treatments, the cells were serum-
starved for two days before adding SiRNA during a 48 h period.
After 6 h, 24 h and 48 h serum induction, XTC.UC1 cells were
harvested for RNA or phospho-protein isolation. To synchronize
the cell cycle for genome-wide expression analysis, the cells were
serum-starved during 7 h before replacing the medium with 20%
SVF medium for 48 h. After 12 h, 24 h and 48 h serum induction
corresponding to 19 h, 31 h and 55 h SiRNA treatment,
XTC.UC1 cells were harvested for protein, DNA and RNA
isolation. We refer to the times of 20% serum induction (T0, T12,
T24 and T48) instead of the times of SiRNA treatment (T7, T19,
T31 and T55) in the figures and the text.
The PRC expression level, analyzed by quantitative RT-PCR,
normalized by b-globin expression, was considered relevant when
PRC mRNA inhibition reached 70% of that of the negative
control (scramble) with a significant effect on COX5B, the PRC-
regulated gene.
Microarray Analysis
cDNA microarray slides were prepared at the Transcriptome
Core Facility of the University of Nantes (INSERM U915,
France), using a set of 20,000 oligonucleotides with full functional
characterization and content referencing (Ocimum Biosolutions,
Hyderabad, India). RNA amplification, cDNA labelling and
hybridization from XTC.UC1 cells were performed using the
protocols recommended by the Transcriptome Core Facility
(http://cardioserve.nantes.inserm.fr/ptf-puce/). Slides were ana-
lyzed with Axon GenePix 4.0 software (Axon, Union City, CA,
USA) after scanning on a ScanArray Express II scanner (Packard
Bioscience, Billerica, MA, USA). Data are available in the GEO
database (GSE 14282) and are confirmed to be MIAME
compliant for raw and normalized data as well as for protocols
used. The hierarchical clustering of the genes was computed on
median-gene-centred and log-transformed data using average
linkage and uncentred correlation distances. Computations and
visualization were performed using Cluster and TreeView
programs [48]. EASE and Gene Set analyses were used to
determine the statistical likelihood that a priori families of genes
were over-represented and differentially expressed [49]. Differen-
tially expressed genes were defined as those well detected in both
groups and with absolute PLS (partial least-squares) loadings .3.0
and t-test values of P,0.0002 (FDR=0.001). In addition, genes
with an absolute value of mean expression differences ,40% were
excluded from further analyses. Gene ontology enrichments in
gene lists were searched for using GOMiner [50]. The most
abundant gene ontology terms, representing at least 5% of the
genes in the lists, with P-values lower than 0.05, were considered
for interpretation.
The over-representation of transcription-factor binding sites
(TFBS) in promoter sequences was investigated with MSignDB
software (GSEA, MIT, MI, USA). We added two more position-
weight matrices to this collection: for the NRF1 transcriptional
factor, we aligned 9 sequences of known NRF-1 binding sites [51];
for the oestrogen-related receptor alpha (ERR1), the position-
weight matrix used was that described by Sladek et al. [52]. The
percentage of representation of a given transcription factor was
compared to its representation in the rest of the microarray.
Western Blot Analysis
Cells were mixed with a buffer containing 10 mmol/L HEPES
(pH 7.9), 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.5% NP-40 and a
protease inhibitor cocktail, and then centrifuged at 13,000 g for
5 min. Supernatants were collected and the protein concentration
was determined by the BCA method (Pierce, Rockford, IL, USA).
Samples containing 30 mg total protein were applied to 12% SDS-
PAGE gel electrophoresis and hybridized with a cocktail of five
antibodies against human nuclear-encoded subunits of the OX-
PHOS process: Complex I (NDUFB8, 20 KDa), complex II (Ip
subunit, 30 KDa); complex III (Core2, 40 KDa); complex IV
(COX2, 24 KDa); complex V (ATPsynthase F1a, 58 KDa), at a
dilution of 1/500 (MS 601, MitoSciences, Eugene, OR, USA). The
level of nitration-modified protein was measured using a high-
activity rabbit polyclonal anti-nitrotyrosine antibody at a dilution of
1/250 (US Biological, Swampscott, MA, USA). The PRC protein
levelwasmeasuredusingarabbitpolyclonalantibodyatthedilution
of 1/5000. This antibody was produced against a human peptide
(1520–1534) we had previously selected (Eurogentec, Seraing,
Belgium). The antibody revealed a unique 170 kDa band on
immunoblots. Ask1 and Elk1 phosphorylation status was evaluated
using at the dilution of 1/500, anti- Ask1(Phospho-Ser83) and
Elk1(Phospho-Ser383) antibodies and anti- unphosphorylated Ask1
and Elk1 antibodies (all from Abcam, Cambridge, UK).
After overnight incubation with primary antibodies, membranes
were washed before incubation with the corresponding horserad-
ish peroxidase (HRP)-conjugated secondary antibody, which was
detected with a chemiluminescent detection system (ECL Plus,
Amersham Biosciences, Fairfield, CT, USA).
Phospho-Specific Protein Microarray Analysis
The phospho-specific protein microarray was obtained from
Full Moon Biosystems (Sunnyvale, CA, USA). Protein microarray
analysis was carried out using the protocol provided by the
manufacturer. Briefly, 100 mg of cell lysate in 50 ml of reaction
mixture were labelled with 1.43 ml biotin in 10 mg/ml N,N-
dimethyformamide. The resulting biotin-labelled proteins were
diluted 1:20 in a coupling solution before being applied to the
array for conjugation. To prepare the antibody microarray, it was
first blocked with a blocking solution for 30 min at room
temperature, rinsed with Milli-Q grade water for three minutes,
and then dried by centrifugation. Finally, the array was incubated
with the biotin-labelled cell lysates at room temperature during
four hours. After the array slide was washed thrice with 50 ml of
1x wash solution for 10 min each, the conjugated-labelled protein
was detected using Cy3-streptavidin.
Data Analysis
Except for the microarray analyses, data are represented as mean
values6SEM, with N representing the number of experiments.
Statistical analyses were performed by a one-way analysis of
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Differences were considered to be statistically significant at
P#0.05. The Pearson chi-squared test was used to compare
quantitative RT-PCR to microarray results.
Supporting Information
Figure S1 Western blot analysis and differential gene expression
data during SiRNA treatment against PRC in XTC.UC1 cell line
(N=5, *P#0.05). S1A: Western blot analysis of PRC expression at
T24andT48 ofSiRNAtreatmentcomparedtocontrol(b-Tubulin).
PRC antibody is raised to the (1520–1534) subregion of the
molecule and reveals a unique band near to 170 kDa on
immunoblots.S1B:AnalysisofphosphorylationstatusforAsk1(Pho-
spho-Ser83) and Elk1(Phospho-Ser383) after 48 h of PRC SiRNA
treatmentcomparedtocontrol.Foreach protein,twoantibodiesare
used raised to phosphorylated and unphosphorylated subregions
revealing 155kDa (Ask1) and 46 kDa (Elk1) bands on immunoblots.
S1C: Comparison of differential gene expression data obtained by
microarrays and real-time RT-PCR after 48 h PRC SiRNA
treatment. The upper and lower limits of each box stand for the
upper and the lower quartiles, respectively; bold lines represent
medians; whiskers represent extreme measurements. Regulation of
genes from cluster 2 (TFAM, COX5B, COX15), cluster 5
(LDH6A1, OSGIN2, PPKAA2) and cluster 6 (CDCA3, CDC14B,
CDC25C) were confirmed on 5 independent SiRNA experiments.
Found at: doi:10.1371/journal.pone.0007964.s001 (5.52 MB TIF)
Table S1 Phospho-specific Antibody Array analysis of PRC
SiRNA XTC.UC1 cells and control. Cell lysates were labeled with
Biotin and incubated with antibody array, separately. Arrays were
washed and labeled proteins were detected by Cy3-streptavidin.
Signal represents the average signal intensity of six replicates. CV:
coefficient of variation.
Found at: doi:10.1371/journal.pone.0007964.s002 (0.23 MB
DOC)
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